Document:

Consulting Agreement, dated March 28, 2007, between the Company and Guy Nissenson.

    Exhibit
      10.100

    

    CONSULTING
      AGREEMENT

    

    This
      Consulting Agreement ("Agreement") is entered into on March 28, 2007, to be
      effective as of January 1, 2007, by and between Xfone,
      Inc.,
      a
      Nevada corporation (the "Company") and Guy
      Nissenson
      (the
      "Consultant").

    

    WHEREAS,
      the
      Consultant has been the President and CEO of the Company (the "Board") since
      the
      inception of the Company, and is indirectly a major shareholder of the Company;
      and

    

    WHEREAS,
      the
      Consultant has expertise in the areas of telecommunication, corporate
      management, finance, investment, mergers and acquisitions, product and service
      strategy, and other areas relating to the business of the Company;
      and

    

    WHEREAS,
      the
      Company desires to avail itself of the expertise of the Consultant in the
      aforesaid areas, in which it acknowledges the expertise of the
      Consultant.

    

    NOW,
      THEREFORE,
      in
      consideration of the foregoing recitals and other good and valuable
      consideration, the Company and the Consultant do hereby agree as
      follows:

    

    APPOINTMENT

    

    
      	1.  	
              The
                Company hereby appoints the Consultant to render the advisory and
                consulting services described below in Section 4 of this Agreement
                (the
                "Services") during the effective term of this Agreement.
                

            

    

    

    
      	2.  	
              In
                connection with the provision of the Services pursuant to this Agreement,
                the Consultant shall report directly and only to the Board and the
                Chairman of the Board.

            

    

    

    
      	3.  	
              It
                is hereby clarified that nothing in this Agreement, including in
                the
                provision of the Services under it, shall derogate from, or conflict
                with,
                any duties and/or responsibilities and/or authority under and/or
                pursuant
                to the Articles of Incorporation and/or the Bylaws of the Company
                and/or
                any rules and/or regulations and/or guidelines of the AMEX and/or
                the TASE
                (and/or any other applicable stock exchange) and/or any rules and/or
                regulations and/or guidelines of the U.S. SEC and/or the ISA (and/or
                any
                other applicable securities commission or authority) and/or the laws
                of
                the state of Nevada and/or any other law and/or act and/or regulation
                that
                applies and/or shall apply to the Consultant due to his position
                as the
                President and CEO of the Company. 

            

    

    

    SERVICES

    

    
      	4.  	
              During
                the effective term of this Agreement, the Consultant shall render
                the
                Company advisory, consulting and other services in relation to the
                business and operations of the Company (excluding its business and
                operations in the United Kingdom), including, without limitation
                in the
                areas set forth above in the foregoing
                recitals.

            

    

     

    
      	5.  	
              The
                Consultant undertakes to faithfully serve the Company and to use
                his best
                efforts to promote the Company’s
                interests.

            

    

     

    
      	6.  	
              During
                the effective term of this Agreement, the Consultant shall not be
                allowed
                to provide advisory or consulting services, substantially similar
                to the
                Services, to any telecommunication company, other than the Company
                (and
                its subsidiaries and affiliates), or to any individual who acts in
                the
                field of telecommunication, unless the provision of such advisory
                and/or
                services was pre-approved by the Board. Such Board approval shall
                be
                subject to the prior recommendation of the Audit Committee of the
                Company
                (the "Audit Committee").

               

              Nothing
                in this Section shall derogate form
                Section 19 of this Agreement. 

            

    

     

    FEES,
      BONUSES AND OPTIONS

    

    
      	7.  	
              In
                consideration of the performance of the Services pursuant to this
                Agreement, the Company shall pay the Consultant a monthly fee of
                Ten
                Thousand British Pounds (£10,000) (the "Fee"). The Consultant shall
                invoice the Company at the end of each calendar month and the Company
                shall make the monthly payment immediately upon receiving such invoice.
                

            

    

    

    Once
      a
      calendar year, and no later than December 15, the Board shall consider approving
      an increase to the Fee. Such Board approval shall be subject to the prior
      review, oversight and recommendation to the Board of both the Audit Committee
      and the Compensation Committee of the Company (the "Compensation Committee").
      However, in the event the Company has not established a Compensation Committee,
      the review, oversight and recommendation to the Board of the Audit Committee
      shall suffice. In connection with the performance of this paragraph, the Audit
      Committee, the Compensation Committee and the Board shall take into account,
      among other factors, growth in the Company’s revenues and/or
      profits.

     

    
      	8.  	
              The
                Board shall, from time to time, and not less than once a calendar
                year,
                consider approving a grant of success bonus to the Consultant (the
                "Bonus"). Such Board approval shall be subject to the prior review,
                oversight and recommendation to the Board of both the Audit Committee
                and
                the Compensation Committee. However, in the event the Company has
                not
                established a Compensation Committee, the review, oversight and
                recommendation to the Board of the Audit Committee shall suffice.
                In
                connection with the performance of this Section, the Audit Committee,
                the
                Compensation Committee and the Board shall take into account, among
                other
                factors, growth in the Company’s revenues and/or profits and/or successful
                completion of transactions or activities by the Company (such as,
                but not
                limited to, reorganization, mergers, acquisitions, capital raisings
                and
                cost cuts). 

            

    

    

    It
      is
      hereby clarified that any Board member, except the Consultant, may, at any
      time
      and from time to time, initiate a Bonus grant to the Consultant, and that in
      such an event the approving process contemplated by this Section shall be set
      in
      motion.

    

    
      	9.  	
              Immediately
                upon the establishment by the Company of any new stock option or
                purchase
                plan or other equity compensation arrangement pursuant to which options
                or
                stock may be acquired by officers, directors, employees, or consultants
                of
                the Company (collectively, "Plan"), the Board shall consider approving
                a
                grant of an appropriate amount of options (or any other applicable
                rights)
                under the Plan to the Consultant. Such Board approval shall be subject
                to
                the prior review, oversight and recommendation to the Board of both
                the
                Audit Committee and the Compensation Committee. However, in the event
                the
                Company has not established a Compensation Committee, the review,
                oversight and recommendation to the Board of the Audit Committee
                shall
                suffice. 

            

    

     

    EXPENSES

    

    
      	10.  	
              In
                addition to the Fee and the Bonus, the Company shall pay directly
                and/or
                reimburse the Consultant for the Consultant's
                Expenses.

            

    

    

    For
      the
      purposes of this Agreement, the term "Expenses" shall mean any and all amounts
      actually paid by the Company and/or by the Consultant, and/or to be paid by
      the
      Company at the Consultant’s direction, including, without limitation (i) costs
      associated with telecommunication services and products, and (ii) costs
      associated with transportation and/or travel (including, but not limited to,
      by
      plane, train, rented car and taxi) and/or accommodation (including, but not
      limited to, at rented flats and hotels) and/or any other board and lodging
      expenses (including, but not limited to, food, restaurants and entertainment)
      which were and/or will be incurred in connection with the performance of the
      Services pursuant to this Agreement. 

    

    
      	11.  	
              The
                Company acknowledges that in order to render the Services pursuant
                to this
                Agreement, the Consultant may be required to travel frequently around
                the
                world. Therefore, in order to enable the Consultant a normal family
                life
                the Company shall bear Expenses which are related to the Consultant's
                spouse. 

            

    

    

    
      	12.  	
              In
                connection with the performance of Section 10 of to this Agreement,
                the
                Consultant shall hold and use, in his sole discretion, credit cards
                in the
                name of the Company (the "Credit Cards").

            

    

    

    It
      is
      hereby clarified that due to the Consultant's position with the Company (i.e.
      President and CEO) the Consultant may from time to time use the Credit Cards
      to
      make certain Company payments and pay certain Company expenses.

    

    
      	13.  	
              All
                reimbursements of Expenses shall be made promptly upon, or as soon
                as
                practicable after presentation by the Consultant to the Company of
                the
                statement in connection therewith.

            

    

    

    TERMINATION

    

    
      	14.  	
              This
                Agreement shall be in effect for an initial fixed term of five (5)
                years,
                beginning on January 1, 2007 (the "Initial Effective Term"), and
                thereafter, unless terminated as provided below, shall automatically
                be
                renewed for additional terms of three (3) years (each, an "Additional
                Effective Term").

            

    

    

    Notwithstanding
      the foregoing, each of the Company and the Consultant shall have the right
      to
      terminate the automatic renewal of this Agreement, for any reason whatsoever,
      by
      a termination notice in writing, to be provided to the other party not less
      than
      six (6) months prior to: (i) the expiration of the Initial Effective Term,
      or
      (ii) the expiration of any Additional Effective Term (the "Notice
      Period").

    

    Notwithstanding
      the foregoing, as long as the Consultant shall command and/or control, directly
      and/or indirectly, including together with others (as well as pursuant to that
      certain Voting Agreement dated September 28, 2004, by and among the Consultant,
      Abraham Keinan and Campbeltown Business Ltd.) and/or by proxies, fifteen percent
      (15%) or more of the voting rights of the Company, if the Company shall choose
      to exercise its right to terminate the automatic renewal of this Agreement,
      the
      Notice Period shall be of not less than twelve (12) months.

     

    
      	15.  	
              Notwithstanding
                the foregoing, the Consultant shall have the right to terminate this
                Agreement, for any reason whatsoever, and at any time, including
                during
                the Initial Effective Term ("Early Termination by the Consultant").
                

            

    

    

    In
      the
      event of Early Termination by the Consultant, the Notice Period shall be of
      not
      less than eight (8) months. 

    

    In
      order
      to remove doubt, in the event of Early Termination by the Consultant, the
      entitlement of the Consultant to the Fee and the Bonus shall be void immediately
      upon the termination of this Agreement, and his rights shall be as set forth
      in
      the Severance Agreement (as defined below in Section 17). 

    

    
      	16.  	
              It
                is hereby clarified that the Notice Period shall constitute a part
                of the
                effective term of this Agreement. Without prejudice to the generality
                of
                the above, during the Notice Period the Company and the Consultant
                shall
                continue to perform this Agreement, and their mutual rights and
                obligations under this Agreement shall not be affected, in any manner
                whatsoever, by the termination notice.

            

    

    

    SEVERANCE
      AGREEMENT 

    

    
      	17.  	
              No
                later than June 30, 2007, the Company and the Consultant shall enter
                into
                a severance agreement providing for an appropriate severance package
                for
                the Consultant (the "Severance Agreement"). The Severance Agreement
                shall,
                inter alia, cover events of termination of the automatic renewal
                of this
                Agreement by the Company or the Consultant, termination of this Agreement
                by the Consultant, and scheduled retirement by the Consultant.
                

            

    

    

    WORK
      PRODUCT 

    

    
      	18.  	
              All
                work product created by the Consultant in connection with the Services
                shall be "work for hire", and the Company shall be the sole rightful
                owner
                under U.S. intellectual property laws, free and clear of all claims
                of
                ownership or otherwise (including the Consultant's). The Consultant
                will
                do any and all things, and execute any and all documents as may be
                appropriate to achieve the objectives of this Section.
                

            

    

    

    NON-COMPETE

    

    
      	19.  	 

    

    
      	a.  	
              The
                Consultant shall not, directly or indirectly, compete with the Company
                (including its subsidiaries and affiliates) and its successors and
                assigns
                during the effective term of this Agreement and for a period of six
                (6)
                months following its termination, for any reason whatsoever.
                

            

    

    

    The
      term
      "not compete" as used herein shall mean, inter alia, that the Consultant shall
      not own, manage, operate, consult or be employed in a business substantially
      similar to, or competitive with, the present business of the Company (including
      its subsidiaries and affiliates) or such other business activity in which the
      Company (including its subsidiaries and affiliates) may substantially engage
      during the effective term of this Agreement.

    

    
      	b.  	
              During
                the effective term of this Agreement and for a period of six (6)
                months
                following its termination, for any reason whatsoever, the Consultant
                will
                neither solicit nor employ any Company employee to engage in a competing
                business, nor solicit the business of any client of the Company or
                prospective client of the Company with respect to whom the Company
                has
                conducted an on-site
                macro-assessment.

            

    

    

    CONFIDENTIALITY

    

    
      	20.  	
              The
                Consultant shall treat as confidential any and all Confidential
                Information related, directly or indirectly, to the Company (including
                its
                subsidiaries and affiliates), and shall not use and/or disclose and/or
                disseminate Confidential Information for purposes other than providing
                the
                Services pursuant to this Agreement.

            

    

    

    For
      purposes of this Agreement, "Confidential Information" shall include, but
      not be limited to, any and all information of a confidential and/or proprietary
      nature which relates to the business, activities, technology, products,
      services, marketing, research and financials of the Company (including its
      subsidiaries and affiliates). The provisions of this Section shall survive
      the
      termination of this Agreement.

    

    MISCELLANEOUS

    

    
      	21.  	 

    

    
      	a.  	
              This
                Agreement and the rights and/or obligations of the parties hereunder
                may
                not be assigned without the prior written consent of both the Company
                and
                the Consultant. 

            

    

    

    
      	b.  	
              This
                Agreement shall inure to the benefit of, and be binding upon, the
                Company
                and the Consultant, and their respective successors and assigns.
                

            

    

    

    
      	c.  	
              No
                amendment or waiver of any provision of this Agreement, or consent
                to any
                departure by either party from any such provision, shall be effective
                unless the same shall be in writing and signed by the parties to
                this
                Agreement, and, in any case, such amendment, waiver or consent shall
                be
                effective only in the specific instance and for the specific purpose
                for
                which it was given.

            

    

    

    
      	d.  	
              This
                Agreement shall constitute the entire agreement between the parties
                with
                respect to the subject matter hereof, and shall supersede all previous,
                oral and/or written, negotiations, commitments, understandings and
                agreements relating to the subject matter
                hereto.

            

    

    

    
      	e.  	
              This
                Agreement shall be governed by, construed and enforced in accordance
                with
                the laws of the State of New York, without regard to choice of law
                principles. Each of the parties hereby irrevocably and unconditionally
                consents to submit to the exclusive jurisdiction of the courts of
                the
                State of New York, located in the County of New York, in any action
                or
                proceeding arising out of or relating to this Agreement.
                

            

    

    

    

    
      
        5

        

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF,
      the
      parties have caused this Agreement to be executed and delivered as of the date
      set forth above.

    

    
      	 	 	Xfone,
              Inc.
	 	 
	 
 	 
 	 
 
	
            	By:  	/s/ Itzhak
              Almog 
	 	
              

            
	 	Chairman
              of the Audit Committee

    

    
      	 	 	 
	 	 
	 
 	 
 	 
 
	
            	By:  	/s/ Guy
              NissensonUnited States Securities & Exchange Commission EDGAR Filing

[Translation]

EXHIBIT 10.1

TRANSACTION, RELEASE AND DISCHARGE

BETWEEN:

ANAPHARM INC. 

(hereinafter called the “Employer”)

AND:

MARC LEBEL

(hereinafter called the “Employee”)

______________________________________________

WHEREAS the Employee has been employed in Quebec, Canada by the Employer, and currently holds the position of Chief Executive Officer and President with the Employer; Employee further serves as an officer and/or director for PharmaNet Development Group, Inc. (“PharmaNet”) and/or its direct and indirect subsidiaries and affiliates (collectively, the “PharmaNet Entities”) (all positions and roles held by Employee with the PharmaNet Entities, including Employer, are referred to herein as the parties’ “Relationships”);

WHEREAS Employee was employed by the Employer pursuant to that certain Employment Agreement dated March 18, 2002 and any amendments thereto (“Employment Agreement”);

WHEREAS Employer does not wish to renew the Employment Agreement when its term expires on March 17, 2007 (the “Separation Date”);

WHEREAS the parties wish to settle amicably any and all disputes between them, including but not limited to any disputes relating to the parties’ Relationships, the termination of the Relationships, or the non-renewal of the Employment Agreement, without any admission;

NOW, THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS:

2

1.

The preamble shall form an integral part of this agreement;

2.

The Employer undertakes to pay the Employee a total gross sum of NINE HUNDRED THIRTY-FIVE THOUSAND AND NINE HUNDRED NINETY DOLLARS (CND $935,990.00), to be paid in equal instalments over twenty-four (24) months on dates that correspond to the Employer’s normal payroll cycle, commencing as soon as reasonably practicable following the first day of the seventh month following the signing of this “Transaction, Release and Discharge”. The payments set forth in this paragraph represent compensation equivalent to twenty-four (24) months’ salary, from which payments the Employer shall make the necessary deductions on account of taxes;

3.

In consideration of the foregoing, the Employee acknowledges that his employment with the Employer has conclusively and permanently terminated, and Employee will be deemed to have resigned from his role as a director (including chairman, if applicable) or officer with any PharmaNet Entity, including Employer; Employee further acknowledges that he has received all amounts of every nature and kind to which he may be entitled as a result of the Relationships, the termination of the Relationships, or the non-renewal of the Employment Agreement, including, without limitation, the amounts that may be owed to him under the Employment Agreement or by way of prior notice or pay in lieu of notice pursuant to his contract of employment, the Civil Code of Québec and the Act respecting labour standards;

4.

The Employee waives the right to take any further proceedings of any kind against any PharmaNet Entity (including but not limited to Employer), predecessor and successor corporations and business entities, past present, and future, and its and their directors, shareholders, officers, employees, insurers and reinsurers, representatives, agents, and employee benefit plans (and the trustees or other individuals affiliated with such plans), past present and future (“Releasees”) for any reason, including but not limited to by reason of any of the Relationships, the termination of the Relationships, or the non-renewal of the Employment Agreement; 

5.

The Employee, on behalf of himself, his heirs, executors, administrators and/or assigns, hereby grants to the Releasees a full, final, and general release and discharge from and in respect of any and all actions, causes of action, suits, claims, debts, claims, proceedings, complaints or demands of every nature and kind, known or unknown, suspected or unsuspected, which Employee, or his heirs, executors, administrators, and/or assigns, ever had or now has against each or any of the Releasees, on account of any cause from the beginning of time to the date of Employee’s execution of this agreement, including but not limited to any and all claims resulting from the Relationships, the termination of the Relationships, or the non-renewal of the Employment Agreement, and any and all claims under any United States or Canadian federal, state, provincial, or local law (including but not limited to any constitution, statute, regulation, ordinance, or common law), 

3

including but not limited to the U.S. Age Discrimination in Employment Act and the New Jersey Conscientious Employee Protection Act. This agreement shall not waive or release any rights or claims that may arise after the date that Employee executes this agreement. In addition, nothing in this agreement shall waive or release Employee's rights to indemnification, if any, under the charter, by-laws, or insurance policies of any PharmaNet Entity.

6.

The Employee agrees that any vested but unexercised stock options must be exercised in accordance with the terms of the applicable stock option plans or grants; any stock options or restricted stock units that have not vested as of the Separation Date shall not vest and shall be forfeited;

7.

Employee expressly acknowledges that the duties and obligations owed by him in the Employment Agreement, including but not limited to the duties set forth in Paragraphs 8, 9, and 12, are continuing and are incorporated herein by reference as if fully set forth herein; in addition, Employee agrees that the duration of the Non-Competition Agreement set forth in section 8(a) of the Employment Agreement and incorporated herein by reference shall be extended to twenty-four (24) months from the Separation Date;

8.

In addition to the Employee’s obligations set out in section 8(b) of the Employment Agreement and in consideration of the foregoing, the Employee undertakes, for a period of twenty-four (24) months starting from the Separation Date, not to solicit, directly or indirectly, the customers of any PharmaNet Entity, not to allow his name to be used to solicit any such customers, and not to take any action aimed at leading or inducing any persons to decide to terminate all or any part of their business relationship with any PharmaNet Entity; 

9.

In addition to the Employee’s obligations set out in section 8(c) of the Employment Agreement and in consideration of the foregoing, the Employee further undertakes, for a period of twenty-four (24) months starting from the Separation Date, not to induce, try to induce or otherwise solicit the personnel of any PharmaNet Entity to leave their employment with such entity and not to hire any PharmaNet Entity’s personnel for any business or enterprise in which the Employee has an interest, as an employee or otherwise; 

10.

Except as required or protected by law, the Employee further undertakes not to do any thing or make any statement (written or oral) that is negative or disparaging of the Releasees, or could in any way harm the reputation or public image of the Releasees;

11.

The parties agree to keep the terms of this agreement confidential except to the extent required or protected by law, in connection with a dispute pertaining to this agreement, or, in the case of the Employer, for legitimate business purposes;

4

12.

Employee confirms that he has returned any and all documents, data, materials and other property of the PharmaNet Entities that he has ever had in his possession, custody, or control, and Employee further confirms that he has cancelled all accounts for his benefit, if any, in the name of any PharmaNet Entity, including but not limited to, credit cards, telephone charge cards, cellular phone, pager, and/or other handheld device accounts, and computer accounts;

13.

Employee acknowledges that he will be deemed an affiliate under SEC Rule 144 promulgated under the Securities Act of 1933, as amended, for a period of three (3) months from the date of the Separation Date, and will remain subject to PharmaNet’s insider trading policy until the later of: (i) PharmaNet’s public release of its financial statements for the quarter ended March 30, 2007; or (ii) Employee is no longer in possession of material non-public information; Employee also acknowledges and agrees that, notwithstanding PharmaNet’s policies, Employee understands that he will remain subject to all United States securities laws and regulations;

14.

Employee shall make himself available at reasonable times (not to exceed more than eight (8) hours per week or twenty (20) hours per month unless additional compensation is provided by the Employer) without further compensation to cooperate with any PharmaNet Entity and its or their attorneys and answer any questions from them regarding the Relationships, his former duties during such Relationships, or any knowledge or information he obtained during such Relationships; such cooperation shall include but not be limited to cooperation in connection with pending litigation, threatened litigation, investigation of claims, investigations by governmental agencies, providing information to, or testifying at deposition, trial, arbitration or other proceeding or otherwise assisting in any litigation, arbitration or other proceeding brought by or against any PharmaNet Entity, or any investigation or proceeding brought by any regulatory or law enforcement agency or legislative body, or testifying or otherwise assisting in a proceeding relating to an alleged violation of any law relating to fraud or any rule or regulation of the Securities and Exchange Commission;

15.

Employee agrees and acknowledges that this agreement is not, and shall not be construed to be, an admission of any violation of any law or duty owed by Releasees to Employee, or of any wrongdoing to Employee by Releasees;

16.

This agreement constitutes the entire agreement between Employee and Employer or Releasees with respect to the subject matter hereof and supersedes all prior negotiations and agreements, whether written or oral, including the Employment Agreement (except for the duties and obligations owed by Employee in the Employment Agreement, including but not limited to the duties set forth in Paragraphs 8, 9, and 12), relating to the subject matter hereof. Employee acknowledges that neither the Employer, the Releasees, nor their agents or attorneys 

5

have made any promise, representation or warranty whatsoever, either express or implied, written or oral, other than the express written representations herein; Employee agrees that this agreement may not be altered, amended, modified, or otherwise changed in any respect except by another written agreement signed by both Employee and Employer;

17.

This agreement is made and entered into in the Province of Quebec and shall be interpreted, enforced, and governed under the law of that Province and the laws of Canada without regard to applicable conflicts of laws principles;

18.

This agreement shall be binding upon Employee and upon his heirs, representatives, executors, administrators, successors and assigns, and shall inure to the benefit of Employer and Releasees, and to their respective heirs, representatives, executors, administrators, successors and assigns;

19.

Employee expressly acknowledges that each of the PharmaNet Entities and Releasees is an intended beneficiary of this agreement, and may enforce this agreement in accordance with its terms. Employee’s duties and obligations hereunder to the PharmaNet Entities and Releasees may not be varied, modified or discharged absent the written consent of the affected companies or individuals.

20.

This agreement is intended to comply with section 409A of the United States Internal Revenue Code and its corresponding regulations and guidance, to the extent applicable. Notwithstanding any provisions of the agreement to the contrary, payments may only be made under the agreement upon an event and in a manner permitted by section 409A of the Code, to the extent applicable. To the extent that any payment under this agreement is deemed to be deferred compensation subject to the requirements of section 409A of the Code, the Employer and the Employee shall amend this agreement so that such payments will be made in accordance with the requirements of section 409A of the Code. Amendment of the agreement to comply with section 409A of the Code will not result in Employee being entitled to receive any enhanced benefit under the agreement.

21.

Employee shall not execute this agreement before March 17, 2007;

22.

This agreement constitutes a transaction within the meaning of articles 2631 and following of the Civil Code of Québec.

23.

Employee further certifies and acknowledges that:

(a)

Employee has read the terms of this agreement and understands its terms and effects, including the fact that he has agreed to RELEASE AND FOREVER DISCHARGE the Releasees from the claims identified in paragraphs 4 and 5; 

6

(b)

Employee has signed this agreement voluntarily and knowingly in exchange for the consideration described herein, which Employee acknowledges is adequate and satisfactory;

(c)

the payments, benefits, promises and undertakings performed, and to be performed, as set forth herein exceed and are greater than the payments and benefits, if any, to which Employee would have been entitled had he not executed this agreement;

(d)

Releasees have advised Employee, through this document, to consult with an attorney concerning this agreement prior to signing this agreement; 

(e)

Employee has been informed that he has the right to consider this agreement for a period of twenty-one (21) days from receipt prior to entering into this agreement and Employee has signed on the date indicated below after concluding that the agreement is satisfactory; and

(f)

Employee may revoke the agreement within seven (7) days after signing it. Revocation must be made by sending a written notice of revocation to Mr. John Hamill, via overnight mail, certified mail or by hand delivery, at 504 Carnegie Center, Princeton, New Jersey 08540. This agreement will not be effective or enforceable until the expiration of this seven (7) day period. The expiration of such revocation period will be the effective date of this agreement. If Employee revokes this agreement, it will not become binding or effective, and Employee will not receive the benefits set forth in this agreement.

IN WITNESS WHEREOF, THE PARTIES HAVE SIGNED THIS AGREEMENT IN DUPLICATE

			
	On this 26th day of March 2007 

 

	 

	On this 17th day of March 2007

	/s/ Jeffrey P. McMullen

	 
	/s/ Marc LeBel

	Anapharm Inc.

Duly authorized representative

	 
	Marc LeBel

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]